JP7181862B2 - 腫瘍浸潤リンパ球および治療の方法 - Google Patents

腫瘍浸潤リンパ球および治療の方法 Download PDF

Info

Publication number
JP7181862B2
JP7181862B2 JP2019520738A JP2019520738A JP7181862B2 JP 7181862 B2 JP7181862 B2 JP 7181862B2 JP 2019520738 A JP2019520738 A JP 2019520738A JP 2019520738 A JP2019520738 A JP 2019520738A JP 7181862 B2 JP7181862 B2 JP 7181862B2
Authority
JP
Japan
Prior art keywords
cells
administered
pharmaceutical composition
item
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520738A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532080A (ja
JP2019532080A5 (enExample
Inventor
ブランデン モリアリティ，
ビュー ウェバー，
モダシール チョードリー，
スティーブン エー． ローゼンバーグ，
ダグラス シー． パーマー，
ニコラス ピー． レスティフォ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2019532080A publication Critical patent/JP2019532080A/ja
Publication of JP2019532080A5 publication Critical patent/JP2019532080A5/ja
Priority to JP2022022792A priority Critical patent/JP2022059055A/ja
Priority to JP2022135735A priority patent/JP2022162155A/ja
Application granted granted Critical
Publication of JP7181862B2 publication Critical patent/JP7181862B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/52—Intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
JP2019520738A 2016-10-18 2017-10-18 腫瘍浸潤リンパ球および治療の方法 Active JP7181862B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022022792A JP2022059055A (ja) 2016-10-18 2022-02-17 腫瘍浸潤リンパ球および治療の方法
JP2022135735A JP2022162155A (ja) 2016-10-18 2022-08-29 腫瘍浸潤リンパ球および治療の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662409651P 2016-10-18 2016-10-18
US62/409,651 2016-10-18
US201762452244P 2017-01-30 2017-01-30
US62/452,244 2017-01-30
PCT/US2017/057228 WO2018075664A1 (en) 2016-10-18 2017-10-18 Tumor infiltrating lymphocytes and methods of therapy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022022792A Division JP2022059055A (ja) 2016-10-18 2022-02-17 腫瘍浸潤リンパ球および治療の方法
JP2022135735A Division JP2022162155A (ja) 2016-10-18 2022-08-29 腫瘍浸潤リンパ球および治療の方法

Publications (3)

Publication Number Publication Date
JP2019532080A JP2019532080A (ja) 2019-11-07
JP2019532080A5 JP2019532080A5 (enExample) 2021-07-26
JP7181862B2 true JP7181862B2 (ja) 2022-12-01

Family

ID=62019385

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019520738A Active JP7181862B2 (ja) 2016-10-18 2017-10-18 腫瘍浸潤リンパ球および治療の方法
JP2022022792A Pending JP2022059055A (ja) 2016-10-18 2022-02-17 腫瘍浸潤リンパ球および治療の方法
JP2022135735A Pending JP2022162155A (ja) 2016-10-18 2022-08-29 腫瘍浸潤リンパ球および治療の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022022792A Pending JP2022059055A (ja) 2016-10-18 2022-02-17 腫瘍浸潤リンパ球および治療の方法
JP2022135735A Pending JP2022162155A (ja) 2016-10-18 2022-08-29 腫瘍浸潤リンパ球および治療の方法

Country Status (8)

Country Link
US (5) US10912797B2 (enExample)
EP (2) EP3529359B1 (enExample)
JP (3) JP7181862B2 (enExample)
CN (1) CN110520530A (enExample)
AU (2) AU2017346885B2 (enExample)
CA (1) CA3041068A1 (enExample)
GB (4) GB2573406B (enExample)
WO (1) WO2018075664A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2698397C (en) 2007-09-18 2018-03-27 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
EA035442B1 (ru) 2011-07-11 2020-06-17 Такеда Вэксинс, Инк. Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
CN108472314A (zh) 2015-07-31 2018-08-31 明尼苏达大学董事会 修饰的细胞和治疗方法
WO2018075664A1 (en) * 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CA3079748A1 (en) * 2017-11-09 2019-05-16 Sangamo Therapeutics, Inc. Genetic modification of cytokine inducible sh2-containing protein (cish) gene
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
CN112368003A (zh) 2018-04-27 2021-02-12 艾欧凡斯生物治疗公司 肿瘤浸润淋巴细胞的基因编辑及其在免疫治疗中的用途
WO2019246261A1 (en) * 2018-06-19 2019-12-26 Regents Of The University Of Minnesota Genome engineering primary monocytes
IL294471B2 (en) 2018-08-13 2024-07-01 Rootpath Genomics Inc High-throughput cloning of bifirate immunoreceptor conjugated polynucleotides and their applications
SG11202101787XA (en) * 2018-09-20 2021-04-29 Iovance Biotherapeutics Inc Expansion of tils from cryopreserved tumor samples
CN113748126A (zh) * 2018-11-30 2021-12-03 因提玛生物科学公司 鉴定免疫调节基因的方法
EP3947436A4 (en) 2019-04-05 2022-12-28 Rootpath Genomics, Inc. COMPOSITIONS AND METHODS FOR ASSEMBLING T LYMPHOCYTE RECEPTOR GENE
US12188045B2 (en) 2019-06-07 2025-01-07 KSQ Therapeutics, Inc. Guide RNA combinations and methods of use
AU2020304022A1 (en) * 2019-06-24 2022-02-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
US20220389381A1 (en) * 2019-10-25 2022-12-08 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN110628717B (zh) * 2019-10-28 2020-10-30 上海科医联创生物科技有限公司 一种浸润性t细胞的培养方法
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
CN115003801A (zh) * 2019-11-27 2022-09-02 得克萨斯大学体系董事会 用于克服肿瘤微环境中的免疫抑制的改造的t细胞和肿瘤浸润性淋巴细胞
JP2023509388A (ja) * 2019-12-18 2023-03-08 セービーオ アクティーゼルスカブ 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス
KR20220119439A (ko) 2019-12-20 2022-08-29 인스틸 바이오 유케이 리미티드 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
KR20230017786A (ko) 2020-04-28 2023-02-06 라이엘 이뮤노파마, 인크. 세포 배양 방법
WO2021222855A1 (en) * 2020-04-30 2021-11-04 The Translational Genomics Research Institute Neoantigen-informed tumor-infiltrating lymphocyte cancer immunotherapy
CN116802309A (zh) * 2020-07-15 2023-09-22 杰克逊实验室 用于sars-cov-2感染的人源化小鼠模型
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022125633A1 (en) * 2020-12-08 2022-06-16 The Regents Of The University Of California Crispr ribonucleoprotein complex genome editing of human innate immune cells
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
KR20230169147A (ko) * 2021-03-11 2023-12-15 더 메서디스트 하스피틀 질환 치료를 위한 방법 및 조성물
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN113952475B (zh) * 2021-09-27 2025-03-11 中国人民解放军陆军军医大学 淋巴细胞和介导crispr系统的纳米复合物联合在制备治疗宫颈癌药物中的应用
WO2023138598A1 (zh) * 2022-01-19 2023-07-27 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞在疾病治疗中的用途
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2025096638A2 (en) * 2023-10-30 2025-05-08 Turnstone Biologics Corp. Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143328A1 (en) 2014-03-20 2015-09-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
JP2018522072A (ja) 2015-07-31 2018-08-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 改変された細胞および治療の方法

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1998006746A2 (en) 1996-08-16 1998-02-19 The Johns Hopkins University School Of Medicine Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
CN1237909A (zh) 1996-10-11 1999-12-08 加利福尼亚大学董事会 联合使用肿瘤细胞与混合淋巴细胞的癌症免疫治疗
US6323317B1 (en) * 1996-11-01 2001-11-27 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostics proteins comprising a SOCS box
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000046386A2 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
JP2000256212A (ja) * 1999-03-05 2000-09-19 Tadayasu Takada 良性間葉系腫瘍の治療剤
EP2311950A1 (en) 2000-01-28 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
EP1330156A4 (en) 2000-10-09 2006-09-13 Amrad Operations Pty Ltd MODULATION OF CYTOKINE OR HORMONE SIGNALING IN AN ANIMAL, INTEGRATING PROGRESSIVE REGULATION OF SOCS SEQUENCE EXPRESSION IN ANIMALS
US8716022B2 (en) 2000-11-17 2014-05-06 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Modulation of meiotic recombination
US7723111B2 (en) 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
PL208712B1 (pl) 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
EP1472341A4 (en) 2002-02-08 2005-06-15 Xcyte Therapies Inc COMPOSITIONS AND METHODS FOR RESTORING IMMUNE RESPONSE IN PATIENTS WITH IMMUNOLOGICAL DEFICIENCIES
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050250207A1 (en) 2002-06-05 2005-11-10 Rozwadowski Kevin L Retrons for gene targeting
DK1545204T3 (en) * 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
DK3211085T3 (da) 2003-09-30 2021-06-21 Univ Pennsylvania Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
WO2006112869A2 (en) 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
US8889365B2 (en) 2005-03-16 2014-11-18 Rutgers, The State University Of New Jersey Methods and kit for detecting breast cancer
CN102994549B (zh) 2005-04-07 2015-02-11 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
EP1898936A4 (en) 2005-06-15 2009-05-06 London Health Sci Ct Res Inc METHOD OF TREATING CANCER BY GENE EXTINCTION USING ARNS
HUE038833T2 (hu) 2005-08-05 2018-11-28 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Antigénspecifikus T-sejtek létrehozása
WO2007025097A2 (en) 2005-08-26 2007-03-01 Danisco A/S Use
US20090220488A1 (en) * 2005-08-31 2009-09-03 Humphrey Gardner Evaluating and treating scleroderma
CN101410525B (zh) 2006-05-17 2012-09-05 弗·哈夫曼-拉罗切有限公司 生产多肽的细胞
ATE530669T1 (de) 2006-05-19 2011-11-15 Danisco Markierte mikroorganismen und entsprechende markierungsverfahren
EP1878744A1 (en) 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
US7750449B2 (en) 2007-03-13 2010-07-06 Micron Technology, Inc. Packaged semiconductor components having substantially rigid support members and methods of packaging semiconductor components
NO2856876T3 (enExample) 2007-03-30 2018-06-30
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US8546553B2 (en) 2008-07-25 2013-10-01 University Of Georgia Research Foundation, Inc. Prokaryotic RNAi-like system and methods of use
PT3006459T (pt) 2008-08-26 2021-11-26 Hope City Método e composições para funcionamento melhorado de efetores antitumorais de células t
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
ES2634118T3 (es) 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
US20120192298A1 (en) 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
US8383099B2 (en) * 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011117258A2 (en) 2010-03-22 2011-09-29 Association Institut De Myologie Methods of increasing efficiency of vector penetration of target tissue
CA3197245A1 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
JP5261448B2 (ja) * 2010-08-09 2013-08-14 古河電気工業株式会社 空孔アシスト光ファイバ
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
WO2012078540A1 (en) * 2010-12-08 2012-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012112079A1 (en) 2011-02-14 2012-08-23 Vitaspero, Inc. IMPROVING CELLULAR IMMUNOTHERAPEUTIC VACCINES EFFICACY WITH GENE SUPPRESSION IN DENDRITIC CELLS AND T-LYMPHOCYTES USING SiRNA
US9528124B2 (en) 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
ES2841983T3 (es) 2011-03-23 2021-07-12 Hutchinson Fred Cancer Res Método y composiciones para inmunoterapia celular
CN103476399A (zh) 2011-04-18 2013-12-25 独立行政法人国立精神·神经医疗研究中心 药剂递送粒子及其制造方法
US20140113376A1 (en) 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
KR101307196B1 (ko) 2011-07-15 2013-09-12 국립대학법인 울산과학기술대학교 산학협력단 미세 세포 배양 장치
EP2756521A4 (en) 2011-09-16 2015-04-22 Univ Pennsylvania RNA-MANIPULATED T-CELLS FOR THE TREATMENT OF CANCER
WO2013049330A1 (en) 2011-09-28 2013-04-04 The Regents Of The University Of California Synthetic transcriptional control elements and methods of generating and using such elements
HK1201565A1 (en) 2011-10-21 2015-09-04 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9688740B2 (en) 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
US11458157B2 (en) 2011-12-16 2022-10-04 Targetgene Biotechnologies Ltd. Compositions and methods for modifying a predetermined target nucleic acid sequence
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
PT2852613T (pt) 2012-05-22 2019-05-20 Us Health Recetores de célula t anti-ny-eso-1 murinos
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
US20160046961A1 (en) 2012-05-25 2016-02-18 Emmanuelle Charpentier Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription
PT2855667T (pt) 2012-05-25 2023-11-22 Cellectis Métodos para modificar geneticamente células t alogénicas e resistentes a imunossupressores para imunoterapia
WO2014006518A1 (en) 2012-07-04 2014-01-09 Indian Institute Of Science Compounds as inhibitor of dna double-strand break repair, methods and applications thereof
JP2015527889A (ja) 2012-07-25 2015-09-24 ザ ブロード インスティテュート， インコーポレイテッド 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
HK1207111A1 (en) 2012-08-03 2016-01-22 加利福尼亚大学董事会 Methods and compositions for controlling gene expression by rna processing
IL269270B (en) 2012-08-20 2022-07-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
JP6401704B2 (ja) * 2012-10-10 2018-10-10 サンガモ セラピューティクス， インコーポレイテッド Ｔ細胞を修飾する化合物およびその使用
US20140113375A1 (en) 2012-10-21 2014-04-24 Lixin Liu Transient Expression And Reverse Transcription Aided Genome Alteration System
KR101706085B1 (ko) 2012-10-23 2017-02-14 주식회사 툴젠 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP2928496B1 (en) 2012-12-06 2019-10-09 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
EP2784162B1 (en) 2012-12-12 2015-04-08 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
CA2894668A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
JP2016501531A (ja) 2012-12-12 2016-01-21 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作および治療適用のための系、方法および組成物の送達、エンジニアリングおよび最適化
CN105121648B (zh) 2012-12-12 2021-05-07 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
ES2701749T3 (es) 2012-12-12 2019-02-25 Broad Inst Inc Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos
US9970024B2 (en) 2012-12-17 2018-05-15 President And Fellows Of Harvard College RNA-guided human genome engineering
WO2014127287A1 (en) 2013-02-14 2014-08-21 Massachusetts Institute Of Technology Method for in vivo tergated mutagenesis
JP6491113B2 (ja) 2013-02-25 2019-03-27 サンガモ セラピューティクス， インコーポレイテッド ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
PL2961831T3 (pl) 2013-02-26 2020-12-14 Memorial Sloan Kettering Cancer Center Kompozycje i sposoby do immunoterapii
AU2014223243B2 (en) 2013-03-01 2019-10-17 Regents Of The University Of Minnesota Talen-based gene correction
WO2014153118A1 (en) 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
ES2901396T3 (es) 2013-03-14 2022-03-22 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
EP2971041B1 (en) 2013-03-15 2018-11-28 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US11311575B2 (en) 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
AU2014266833B2 (en) 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
EP3730615A3 (en) 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
AU2014273082B2 (en) 2013-05-29 2018-11-08 Cellectis A method for producing precise DNA cleavage using Cas9 nickase activity
EP3004337B1 (en) 2013-05-29 2017-08-02 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
JP6195474B2 (ja) 2013-05-31 2017-09-13 ギガフォトン株式会社 極端紫外光生成装置及び極端紫外光生成システムにおけるレーザシステムの制御方法
EP3011035B1 (en) 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
SG10201710487VA (en) 2013-06-17 2018-01-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Viral Components
EP3011030B1 (en) 2013-06-17 2023-11-08 The Broad Institute, Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
EP3825406A1 (en) 2013-06-17 2021-05-26 The Broad Institute Inc. Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
WO2014204724A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
EP3620524A1 (en) 2013-06-17 2020-03-11 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
JPWO2015002293A1 (ja) * 2013-07-05 2017-02-23 学校法人 岩手医科大学 Ｗｎｔシグナル阻害剤
EP3019595A4 (en) 2013-07-09 2016-11-30 THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
RU2748433C2 (ru) * 2013-07-10 2021-05-25 Президент Энд Фэллоуз Оф Харвард Коллидж ОРТОГОНАЛЬНЫЕ БЕЛКИ Cas9 ДЛЯ РНК-НАПРАВЛЯЕМОЙ РЕГУЛЯЦИИ И РЕДАКТИРОВАНИЯ ГЕНОВ
US20150020233A1 (en) 2013-07-12 2015-01-15 Oms Investments, Inc. Plants comprising events pp009-401, pp009-415, and pp009-469, compositions, sequences, and methods for detection thereof
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
US20150044772A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
CA2922089C (en) 2013-08-22 2022-07-05 E. I. Du Pont De Nemours And Company Plant genome modification using guide rna/cas endonuclease systems and methods of use
CN104427476B (zh) 2013-09-10 2019-05-07 中兴通讯股份有限公司 位置信息上报方法、集群服务处理方法及系统
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
US20160237455A1 (en) 2013-09-27 2016-08-18 Editas Medicine, Inc. Crispr-related methods and compositions
DE102013111099B4 (de) 2013-10-08 2023-11-30 Eberhard Karls Universität Tübingen Medizinische Fakultät Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA
US20150098954A1 (en) 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
KR102523466B1 (ko) 2013-11-07 2023-04-20 에디타스 메디신, 인코포레이티드 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
US20160298096A1 (en) 2013-11-18 2016-10-13 Crispr Therapeutics Ag Crispr-cas system materials and methods
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
US10557151B2 (en) 2013-11-28 2020-02-11 Horizon Discovery Limited Somatic human cell line mutations
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
EP3470089A1 (en) 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
CN103820454B (zh) 2014-03-04 2016-03-30 上海金卫生物技术有限公司 CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA
PL3116902T3 (pl) 2014-03-11 2020-07-27 Cellectis Sposób wytwarzania limfocytów T kompatybilnych do przeszczepienia alogenicznego
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
US11439712B2 (en) 2014-04-08 2022-09-13 North Carolina State University Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
EP3129488B1 (en) 2014-04-10 2019-06-12 The Regents of The University of California Methods and compositions for using argonaute to modify a single stranded target nucleic acid
EP3800248A3 (en) 2014-04-18 2021-08-04 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
PT4219687T (pt) 2014-04-23 2024-10-02 Juno Therapeutics Inc Métodos para isolamento, cultura, e manipulação genetica de populações de células imunes para terapêutica adotiva
WO2015188056A1 (en) 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Methods and compositions for nuclease design
EP3155116A4 (en) 2014-06-10 2017-12-27 Massachusetts Institute Of Technology Method for gene editing
JP2017524348A (ja) 2014-06-10 2017-08-31 モナッシュ ユニバーシティ 養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法
TWI530276B (zh) 2014-07-08 2016-04-21 原相科技股份有限公司 具去噪功能之生理偵測模組及其生理偵測方法
MX2017000646A (es) 2014-07-15 2017-04-27 Juno Therapeutics Inc Celulas geneticamente modificadas para terapia celular adoptiva.
BR112017001818A2 (pt) * 2014-07-29 2017-11-21 Pfizer receptores antigênicos quiméricos específicos para egfrviii para imunoterapia de câncer
EP3201340B1 (en) 2014-10-01 2020-12-02 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
CN119409799A (zh) 2014-10-02 2025-02-11 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
AU2015339744B2 (en) 2014-10-31 2021-03-25 The Trustees Of The University Of Pennsylvania Altering gene expression in CART cells and uses thereof
US10900034B2 (en) 2014-12-03 2021-01-26 Agilent Technologies, Inc. Guide RNA with chemical modifications
SG11201704272YA (en) 2014-12-31 2017-06-29 Synthetic Genomics Inc Compositions and methods for high efficiency in vivo genome editing
WO2016112351A1 (en) 2015-01-09 2016-07-14 Bio-Rad Laboratories, Inc. Detection of genome editing
CN107429263A (zh) 2015-01-15 2017-12-01 斯坦福大学托管董事会 调控基因组编辑的方法
KR102422108B1 (ko) 2015-01-20 2022-07-19 삼성디스플레이 주식회사 유기 발광 표시 장치
CN107847524A (zh) 2015-03-27 2018-03-27 哈佛学院校长同事会 经过修饰的t细胞及其制备和使用方法
CN108136047B (zh) 2015-05-13 2022-12-13 西雅图儿童医院（Dba西雅图儿童研究所） 提高原代细胞中基于核酸内切酶的基因编辑
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CA2991301A1 (en) 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CA3008289C (en) 2015-12-16 2023-10-31 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced sh2 protein in nk cells
US9570114B1 (en) 2016-01-15 2017-02-14 HGST Netherlands B.V. Laminated film-packed hard disk drive for hermetic sealing
US11746349B2 (en) 2016-02-09 2023-09-05 President And Fellows Of Harvard College DNA-guided gene editing and regulation
NZ750005A (en) * 2016-07-07 2023-06-30 Iovance Biotherapeutics Inc Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
WO2018075664A1 (en) * 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
JP2019531755A (ja) 2016-10-27 2019-11-07 インティマ バイオサイエンス， インコーポレイテッド 遺伝子改変細胞を作製するウイルス法
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
CA3074872A1 (en) 2017-09-07 2019-03-14 The Board Of Trustees Of The Leland Stanford Junior University Nuclease systems for genetic engineering

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143328A1 (en) 2014-03-20 2015-09-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
JP2018522072A (ja) 2015-07-31 2018-08-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 改変された細胞および治療の方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Exp. Med. 2015, Vol. 212, No.12, pp.2095-2113
日泌尿会誌, 84巻, 10号, 1993年: 1759～1767

Also Published As

Publication number Publication date
GB2605540A (en) 2022-10-05
EP4338799A2 (en) 2024-03-20
JP2022059055A (ja) 2022-04-12
US20200289571A1 (en) 2020-09-17
US11154574B2 (en) 2021-10-26
CA3041068A1 (en) 2018-04-26
JP2019532080A (ja) 2019-11-07
EP3529359B1 (en) 2023-12-13
EP3529359A1 (en) 2019-08-28
GB202113770D0 (en) 2021-11-10
WO2018075664A1 (en) 2018-04-26
AU2017346885B2 (en) 2021-10-21
US10912797B2 (en) 2021-02-09
AU2017346885A1 (en) 2019-05-16
GB2573406A (en) 2019-11-06
GB202209032D0 (en) 2022-08-10
JP2022162155A (ja) 2022-10-21
US20190008899A1 (en) 2019-01-10
GB202205417D0 (en) 2022-05-25
CN110520530A (zh) 2019-11-29
US20220105133A1 (en) 2022-04-07
GB2605883B (en) 2023-03-15
GB2604416B (en) 2023-03-15
GB2605540B (en) 2022-12-21
AU2022200267A1 (en) 2022-02-10
GB201906855D0 (en) 2019-06-26
US20200289570A1 (en) 2020-09-17
GB2604416A (en) 2022-09-07
GB2573406B (en) 2021-11-10
GB2605883A (en) 2022-10-19
EP4338799A3 (en) 2024-06-05
EP3529359A4 (en) 2020-06-03
US20200330517A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
JP7181862B2 (ja) 腫瘍浸潤リンパ球および治療の方法
US11925664B2 (en) Intracellular genomic transplant and methods of therapy
Diorio et al. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
US20250205335A1 (en) Synthetic tumor-infiltrating lymphocytes (tils)
HK40017947A (en) Tumor infiltrating lymphocytes and methods of therapy
HK1256380B (en) Modified cells and methods of therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220829

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220907

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220929

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221027

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221118

R150 Certificate of patent or registration of utility model

Ref document number: 7181862

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250